Skip to main content

Table 4 Impact of EGFR polymorphisms on histopathological features and prognostic estimates of breast cancer

From: Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer

  R497Kvariant genotypes (CA)nvariant genotypes EGFRcombined variant genotypes
Lymph node status TNM status ERR PR status TNM status ERR TNM status ERR
Tumor stratification N2/N3 ≥ IIIA High negative ≥ IIIA High ≥ IIIA High
OR adjusted OR adjusted OR OR adjusted OR adjusted OR OR adjusted OR
(IC95%) (IC95%) (IC95%) (IC95%) (IC95%) (IC95%) (IC95%) (IC95%)
  P P P P P P P P
Complete cohort 0.32 0.34 0.50 0.42 0.74 0.74 0.22 0.25
  (0.17-0.59) (0.19-0.63) (0.30-0.81) (0.19-0.91) (0.40-1.32) (0.43-1.25) (0.07-0.75) (0.09-0.71)
< 0.001 0.001 0.005 0.030 0.53 0.26 0.018 0.005
Luminal A 0.34 0.38 0.35 NA 0.62 0.60 0.32 0.24
  (0.15-0.75) (0.18-0.80) (0.17-0.75)   (0.29-1.36) (0.27-1.32) (0.092-1.12) (0.06-1.03)
0.007 0.011 0.005   0.22 0.20 0.075 0.038
Luminal B 0.057 0.060 0.58 0.080 1.29 1.29 NC 0.61
  (0.006-0.53) (0.007-0.53) (0.21-1.60) (0.012-0.54) (0.35-4.72) (0.48-3.48)   (0.12-3.10)
0.012 0.012 0.29 < 0.001 0.26 0.62   0.54
HER2-like 0.18 0.22 0.27 NA 1.14 2.91 NC NC
  (0.02-2.02) (0.02-2.28) (0.05-1.64)   (0.15-8.59) (0.27-31.21)   
0.18 0.22 0.14   0.90 0.36   
Triple negative 5.2 5.1 2.0 NA NC NC NC NC
  (0.48-55.27) (0.48-54.03) (0.48-8.40)      
  0.17 0.18 0.349      
  1. R497K variant genotypes include Arg/Lys and Lys/Lys. The genotype Arg/Arg was taken as reference for OR calculation; (CA)n variant genotypes include two Long alleles in combination (Long/Long), where the Long allele corresponds to (CA)n lengths with more than 16 repeats. The genotypes Short/Short and Short/Long were considered together as reference for OR calculation. EGFR combined variants include patients with genotypes Arg/Lys or Lys/Lys for R497K and Long/Long for (CA)n. The reference genotypes were R497K Arg/Arg and (CA)n Short/Short or Short/Long. The OR calculation for lymph node status was adjusted for age, hystological type, tumor grade, tumor size, and for ER, PR and HER2 status. The OR calculation for PR status was adjusted for age, hystological type, tumor grade, tumor size, lymph node status and for ER and HER2 status. The OR calculation for TNM status was adjusted for age, hystological type, tumor grade and for ER, PR and HER2 status. Statistically significant differences are presented in bold characters. Abbreviations: TNM Tumor staging according to tumor size, lymph node status and distant metastases, ERR Estimated Recurrence Risk, PR Progesterone Receptor, HER2 Human Epidermal growth factor Recetor 2, NA not applicable, NC not calculated (the number of samples was not sufficient for OR calculation).